Search
Scorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedEnvenomation by a scorpion sting can result in serious cardiovascular effects [A32483]. … It was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies.
Butorphanol
go.drugbank.com/drugs/DB00611ApprovedIllicitVet approvedA synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Carprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnCarprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs.
Perfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]
Sodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnSodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing.
Fluoride ion F-18
go.drugbank.com/drugs/DB09398ApprovedInvestigationalIt contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503].
XP12B
go.drugbank.com/drugs/DB04928InvestigationalXP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion